Search results:
General Information
| Gene_Symbol | Gene_ID | Gene_Name | Chromosome | Alias |
|---|---|---|---|---|
| E2F1 | 1869 | E2F transcription factor 1 | 20 | RBP3; E2F-1; RBAP1; RBBP3 |
- Evidence
- Gene
- mRNA
- CDS
- Protein
- PTM
- Enzyme
- PPi
- Pathway
- Structural
- Domain
- Ontology
- SNP
- Drug
- External Links
Evidence Information
| Pubmed ID | Year | Sample Information | Techniques | Mechanism | Fold Change | Remark |
|---|---|---|---|---|---|---|
| 18794899 | 2008 | Cell line : SW 480, DLD 1, U 2OS-shRb ,Saos 2-TR-E2F1 Source : - Sample Type : - No. of Sample : - Stage : - | Fly stocks, transgenes, and genetic crosses, Cell Culture and Gene Transfer, Luciferase Reporter. | Down-regulation | - | E2F1 deregulation suppresses beta-catenin activity in an APC/GSK3 -independent manner, reducing the expression of key beta-catenin targets including c-MYC. E2F1 activity is also repressed by CDK8, a colorectal oncoprotein. Inhibition of CDK8 combined with the activation of E2F1, may be useful to target cancer cells that are driven by deregulated beta-catenin activity. |
| 22688350 | 2012 | Cell line : - Source : - Sample Type : CRC tumor and Normal tissue No. of Sample : 100 Stage : - | Immunohistochemistry, serial section analysis for kinetics study. | Down-regulation | - | E2F1 and E2F4 expressed nuclear immunopositivity in all 100 cases. A mutually exclusive immunostaining pattern between E2F1 and E2F4 and a direct correlation of E2F1 and apoptosis were also observed. The inverse immunohistochemical relationship between E2F1 and E2F4 indicates a possible mechanistic interlink in colorectal cancer. |
| 23023523 | 2012 | Cell line : - Source : Sixth People Hospital affiliated to Shanghai Jiaotong University. Sample Type : - No. of Sample : - Stage : - | Immunohistochemistry with tissue microarrays, real time RT- PCR, MTT . | Down-regulation | - | - |
| 22241525 | 2012 | Cell line : HT 29, HCT 116 Source : - Sample Type : - No. of Sample : - Stage : - | - | Down-regulation | - | let 7e and miR-17 were initially upregulated and than downregulated in advanced CRC cancer in HT29 and HCT116 cell line and both miRNA targets E2F1 gene. E2F1, an upstream regulator of TP53. |
| 22327218 | 2012 | Cell line : U 2OS, C 33A, MCF 7, HCT 116, SAOS 2, HeLa, H 1299 Source : - Sample Type : - No. of Sample : - Stage : - | Transfection, SiRNA , Flow cytometry,Proliferation rate determination using Hemocytometer. | Methylation | - | E2F-1 is methylated in tumour cells, and a reduced level of methylation is evident under DNA damage conditions that allow E2F-1 stabilization and give rise to apoptosis. Arginine methylation regulates the biological activity of E2F-1 activity, and raise the possibility that arginine methylation contributes to tumourigenesis by influencing the E2F pathway. |
| 20812030 | 2011 | Cell line : Caco 2 Source : - Sample Type : - No. of Sample : - Stage : - | Cell culture and SiRNA transfection, Quantitative DNA fragmentation assay, Caspase assay. | Unknown | - | Upregulation of E2F1 and p73 increased the expression of Siva and PUMA, respectively and promote Nutlin-3 induced caspase-3 activation. The knockdown of E2F significantly decreased Siva-1 expression and decreased caspase-3 activation in response to Nutlin-3. Nutlin-3 induced apoptosis by increasing the p73- and E2F1-mediated expression of BH-3 only family proteins. |
Gene Details
| Gene Type | protein coding |
|---|---|
| Gene Family | - |
| Description | The protein encoded by this gene is a member of the E2F family of transcription factors. The E2F family plays a crucial role in the control of cell cycle and action of tumor suppressor proteins and is also a target of the transforming proteins of small DNA tumor viruses. The E2F proteins contain several evolutionally conserved domains found in most members of the family. These domains include a DNA binding domain, a dimerization domain which determines interaction with the differentiation regulated transcription factor proteins (DP), a transactivation domain enriched in acidic amino acids, and a tumor suppressor protein association domain which is embedded within the transactivation domain. This protein and another 2 members, E2F2 and E2F3, have an additional cyclin binding domain. This protein binds preferentially to retinoblastoma protein pRB in a cell-cycle dependent manner. It can mediate both cell proliferation and p53-dependent/independent apoptosis. [provided by RefSeq, Jul 2008] | Chromosome | 20 |
| Location | 20q11.2 |
| Start | 33675486 |
| End | 33686404 |
| Strand | - |
| Gene Sequence | Download Select all |
| Length | 10919 |
| OMIM ID | 189971 |
| HGNC ID | HGNC:3113 |
| Unigene ID | Hs.654393 |
| Ensembl ID | ENSG00000101412 |
| PharmGKB ID | PA152 |
mRNA Information
| mRNA ID | NM_005225.2 |
|---|---|
| Exon | join(1..401,5989..6079,6431..6650,8052..8204,8865..8979, 9075..9300,9426..10919) | mRNA Sequence | Download Select all |
| Length | 2722 |
CDS Information
| Location | join(141..401,5989..6079,6431..6650,8052..8204,8865..8979, 9075..9300,9426..9673) |
|---|---|
| CDS Sequence | Download Select all |
| CCDS ID | CCDS13224.1 |
Protein Information
| Protein ID | NP_005216.1 |
|---|---|
| Protein Name | E2F transcription factor 1 |
| Molecular Wt. (Da) | 46789 |
| Protein Sequence | Download Select all |
| Length | 437 |
| Uniprot ID | Q16611 |
| Ensembl Protein ID | ENSP00000363591 |
Post-translational Modification Information (Source : HPRD)
| Residue | Type | site |
|---|---|---|
| S | Phosphorylation | 403 |
| T | Phosphorylation | 433 |
| S | Phosphorylation | 364 |
| S | Phosphorylation | 31 |
| S | Phosphorylation | 31 |
| S | Phosphorylation | 403 |
| T | Phosphorylation | 433 |
| S | Phosphorylation | 332 |
| S | Phosphorylation | 337 |
| S | Phosphorylation | 375;- |
Enzyme Information
No matching records could be found.
PPi Information
(Click to view network : Source STRING) View
| Interactant Gene ID (Source: HPRD) | Gene Symbol | HPRD ID | Ref Seq ID | Technique | References |
|---|---|---|---|---|---|
| 672 | BRCA1 | 218 | NP_009231.2 | in vitro;in vivo | 924 435 011 278 247 |
| 890 | CCNA2 | 453 | NP_001228.1 | in vitro | 12501191 |
| 1018 | CDK3 | 446 | NP_001249.1 | in vivo | 117 330 018 846 921 |
| 1387 | CREBBP | 2534 | NP_004371.2 | in vitro;in vivo | 8932363 |
| 2932 | GSK3B | 5418 | NP_002084.2 | in vivo | 18367454 |
| 4790 | NFKB1 | 1238 | NP_003989.2 | in vitro;in vivo | 9368006 |
| 5245 | PHB | 1454 | NP_002625.1 | in vitro;in vivo | 1 052 363 314 637 150 |
| 6667 | SP1 | 1796 | NP_612482.2 | in vitro;in vivo | 1 054 728 110 850 420 |
| 7027 | TFDP1 | 1792 | NP_009042.1 | in vitro;in vivo | 88 165 028 405 995 |
Pathway Information
| Pathway Name | Pathway ID |
|---|---|
| Bladder cancer | hsa05219 |
| Cell cycle | hsa04110 |
| Chronic myeloid leukemia | hsa05220 |
| Glioma | hsa05214 |
| Hepatitis B | hsa05161 |
| HTLV-I infection | hsa05166 |
| Melanoma | hsa05218 |
| MicroRNAs in cancer | hsa05206 |
| Non-small cell lung cancer | hsa05223 |
| Pancreatic cancer | hsa05212 |
| Pathways in cancer | hsa05200 |
| Prostate cancer | hsa05215 |
| Small cell lung cancer | hsa05222 |
Structure Information
| PDB ID | 1H24 |
|---|---|
| Resolution | 2.5 |
| Method | X-RAY DIFFRACTION |
| Chains | A,C,G |
| Molecule | CELL DIVISION PROTEIN KINASE 2 |
| Model | View |
Domain Information
| ID | Location | Description |
|---|---|---|
| cd14660 | 202-301 | E2F_DD |
| cl22411 | 202-301 | E2F_DD superfamily |
| pfam02319 | 127-192 | E2F_TDP |
| cl03534 | 127-192 | E2F_TDP superfamily |
Ontology Information
| HPRD ID | 2744 |
|---|---|
| Molecular Class | Transcription factor |
| Molecular Function | Receptor signaling complex scaffold activity (GO:0030159) |
| Biological Process | Apoptosis (GO:0006915) |
Drug Information
No matching records could be found.